Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ENTEREG

« Back to Dashboard
Entereg is a drug marketed by Cubist Pharms and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.

This drug has fifty patent family members in twenty-eight countries.

The generic ingredient in ENTEREG is alvimopan. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alvimopan profile page.

Summary for Tradename: ENTEREG

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1

Pharmacology for Tradename: ENTEREG

Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists

Clinical Trials for: ENTEREG

Entereg Laparoscopic Colon Resection Study
Status: Recruiting Condition: Laparoscopic Colonic Resection

Alvimopan and Ileus in PSF
Status: Recruiting Condition: Ileus; Spinal Fusion

A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy
Status: Completed Condition: Postoperative Ileus

Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
Status: Completed Condition: Ileus

Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair
Status: Recruiting Condition: Ventral Hernia

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Status: Completed Condition: Bowel Dysfunction; Constipation

Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
Status: Completed Condition: Ileus

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Status: Completed Condition: Bowel Dysfunction; Constipation

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Status: Completed Condition: Bowel Dysfunction; Constipation

Accelerating Gastrointestinal Recovery
Status: Recruiting Condition: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms
ENTEREG
alvimopan
CAPSULE;ORAL021775-001May 20, 2008RXYes5,250,542<disabled>YY<disabled>
Cubist Pharms
ENTEREG
alvimopan
CAPSULE;ORAL021775-001May 20, 2008RXYes8,112,290<disabled><disabled>
Cubist Pharms
ENTEREG
alvimopan
CAPSULE;ORAL021775-001May 20, 2008RXYes6,469,030<disabled><disabled>
Cubist Pharms
ENTEREG
alvimopan
CAPSULE;ORAL021775-001May 20, 2008RXYes8,645,160<disabled><disabled>
Cubist Pharms
ENTEREG
alvimopan
CAPSULE;ORAL021775-001May 20, 2008RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ENTEREG

Country Document Number Publication Date
Finland921345Sep 30, 1992
Norway178398Mar 20, 1996
China1065455Oct 21, 1992
Australia3970501Jun 18, 2001
HungaryT66596Dec 28, 1994
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc